E D Kantor1, J W Lampe, U Peters, D D Shen, T L Vaughan, E White. 1. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N., Mailbox M4-B402, Seattle, WA 98109, USA. ekantor@fhcrc.org
Abstract
PURPOSE: Glucosamine and chondroitin are non-vitamin, non-mineral supplements which have anti-inflammatory properties. These supplements are typically used for joint pain and osteoarthritis and are commonly taken as either glucosamine alone or glucosamine plus chondroitin. An exploratory analysis conducted within the VITamins And Lifestyle (VITAL) study observed any use of glucosamine and chondroitin to be associated with reduced risk of colorectal cancer (CRC) after 5 years of follow-up. METHODS: With two additional years of follow-up, we have studied these associations in greater depth, including associations by frequency/duration of use and by formulation, and have evaluated whether observed associations are modified by factors associated with inflammation. Participants include 75,137 western Washington residents aged 50-76 who completed the mailed VITAL questionnaire between 2000 and 2002. Use of glucosamine and chondroitin was ascertained by questions about supplement use during the 10-year period prior to baseline, and participants were followed for CRC through 2008 (n = 557). Cox regression was used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs). RESULTS: Persons reporting use of glucosamine + chondroitin on 4+ days/week for 3+ years had a non-statistically significant 45 % lower CRC risk than non-users (HR: 0.55; 95 % CI 0.30-1.01; p-trend: 0.16). This association varied by body mass index (p-interaction: 0.006), with inverse association observed among the overweight/obese (p-trend: 0.02), but not among the underweight/normal weight. Use of glucosamine alone was not significantly associated with CRC risk. CONCLUSIONS: There is great need to identify safe and effective cancer preventive strategies, suggesting that glucosamine and chondroitin may merit further attention as a potential chemopreventive agent.
PURPOSE:Glucosamine and chondroitin are non-vitamin, non-mineral supplements which have anti-inflammatory properties. These supplements are typically used for joint pain and osteoarthritis and are commonly taken as either glucosamine alone or glucosamine plus chondroitin. An exploratory analysis conducted within the VITamins And Lifestyle (VITAL) study observed any use of glucosamine and chondroitin to be associated with reduced risk of colorectal cancer (CRC) after 5 years of follow-up. METHODS: With two additional years of follow-up, we have studied these associations in greater depth, including associations by frequency/duration of use and by formulation, and have evaluated whether observed associations are modified by factors associated with inflammation. Participants include 75,137 western Washington residents aged 50-76 who completed the mailed VITAL questionnaire between 2000 and 2002. Use of glucosamine and chondroitin was ascertained by questions about supplement use during the 10-year period prior to baseline, and participants were followed for CRC through 2008 (n = 557). Cox regression was used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs). RESULTS:Persons reporting use of glucosamine + chondroitin on 4+ days/week for 3+ years had a non-statistically significant 45 % lower CRC risk than non-users (HR: 0.55; 95 % CI 0.30-1.01; p-trend: 0.16). This association varied by body mass index (p-interaction: 0.006), with inverse association observed among the overweight/obese (p-trend: 0.02), but not among the underweight/normal weight. Use of glucosamine alone was not significantly associated with CRC risk. CONCLUSIONS: There is great need to identify safe and effective cancer preventive strategies, suggesting that glucosamine and chondroitin may merit further attention as a potential chemopreventive agent.
Authors: K M Jordan; N K Arden; M Doherty; B Bannwarth; J W J Bijlsma; P Dieppe; K Gunther; H Hauselmann; G Herrero-Beaumont; P Kaklamanis; S Lohmander; B Leeb; M Lequesne; B Mazieres; E Martin-Mola; K Pavelka; A Pendleton; L Punzi; U Serni; B Swoboda; G Verbruggen; I Zimmerman-Gorska; M Dougados Journal: Ann Rheum Dis Date: 2003-12 Impact factor: 19.103
Authors: Griffith A Bell; Elizabeth D Kantor; Johanna W Lampe; Danny D Shen; Emily White Journal: Eur J Epidemiol Date: 2012-07-25 Impact factor: 8.082
Authors: R Largo; M A Alvarez-Soria; I Díez-Ortego; E Calvo; O Sánchez-Pernaute; J Egido; G Herrero-Beaumont Journal: Osteoarthritis Cartilage Date: 2003-04 Impact factor: 6.576
Authors: Jessie Satia-Abouta; Ruth E Patterson; Irena B King; Kayla L Stratton; Ann L Shattuck; Alan R Kristal; John D Potter; Mark D Thornquist; Emily White Journal: Am J Epidemiol Date: 2003-05-15 Impact factor: 4.897
Authors: Emily White; Ruth E Patterson; Alan R Kristal; Mark Thornquist; Irena King; Ann L Shattuck; Ilonka Evans; Jessie Satia-Abouta; Alyson J Littman; John D Potter Journal: Am J Epidemiol Date: 2004-01-01 Impact factor: 4.897
Authors: Elizabeth D Kantor; Johanna W Lampe; Thomas L Vaughan; Ulrike Peters; Colin D Rehm; Emily White Journal: Am J Epidemiol Date: 2012-11-08 Impact factor: 4.897
Authors: Elizabeth D Kantor; Xuehong Zhang; Kana Wu; Lisa B Signorello; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci Journal: Int J Cancer Date: 2016-07-18 Impact factor: 7.396
Authors: Asma A Khan; Vij Mannan; Muhammad Ahad Pervaiz; Aqsa Akram; Elina S Momin; Muhammad Sanusi; Tejasvi Kashyap; Abeer O Elshaikh Journal: Cureus Date: 2022-05-27
Authors: Elizabeth D Kantor; Kelli O'Connell; Peter S Liang; Sandi L Navarro; Edward L Giovannucci; Mengmeng Du Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-03-01 Impact factor: 4.090
Authors: Elizabeth D Kantor; Christina C Newton; Edward L Giovannucci; Marjorie L McCullough; Peter T Campbell; Eric J Jacobs Journal: Cancer Causes Control Date: 2018-02-06 Impact factor: 2.506
Authors: Elizabeth D Kantor; Kelli O'Connell; Mengmeng Du; Chao Cao; Xuehong Zhang; Dong Hoon Lee; Yin Cao; Edward L Giovannucci Journal: J Altern Complement Med Date: 2020-12-07 Impact factor: 2.579
Authors: Jessica M Moon; Peter Finnegan; Richard A Stecker; Hanna Lee; Kayla M Ratliff; Ralf Jäger; Martin Purpura; Carolyn M Slupsky; Maria L Marco; Craig J Wissent; Jason Theodosakis; Chad M Kerksick Journal: Nutrients Date: 2021-06-24 Impact factor: 5.717